Homology Medicines (Homology Medicines) Tangible Book per Share : $22.65 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Homology Medicines's tangible book value per share for the quarter that ended in Dec. 2023 was $22.65.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.

Homology Medicines Tangible Book per Share Historical Data

The historical data trend for Homology Medicines's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Tangible Book per Share Chart

Homology Medicines Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tangible Book per Share

Get a 7-Day Free Trial

103.14

70.19

53.43

55.73

22.65

Homology Medicines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tangible Book per Share	Get a 7-Day Free Trial															55.73	47.31	37.18	27.42	22.65

Competitive Comparison of Homology Medicines's Tangible Book per Share

For the Biotechnology subindustry, Homology Medicines's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Homology Medicines's Price-to-Tangible-Book falls into.

Homology Medicines Tangible Book per Share Calculation

Homology Medicines's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)	/	Shares Outstanding (EOP)
	=	(72.991	-	0	-	0)	/	3.22319
	=	22.65

Homology Medicines's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)	/	Shares Outstanding (EOP)
	=	(72.991	-	0	-	0)	/	3.22319
	=	22.65

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.

Homology Medicines (NAS:FIXX) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Homology Medicines Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Homology Medicines's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (Homology Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » Tangible Book per Share

Comparable Companies

Traded in Other Exchanges

35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Executives

Paul Alloway	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour	officer: Chief Scientific Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum	officer: Chief Commercial Officer	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith	officer: CFO, Treasurer & Secretary	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos	director, officer: President & CEO	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: *Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty	officer: Chief Operating Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109